HU229455B1 - Formulation comprising testosteron undecanoate and castor oil - Google Patents

Formulation comprising testosteron undecanoate and castor oil

Info

Publication number
HU229455B1
HU229455B1 HU0200453A HUP0200453A HU229455B1 HU 229455 B1 HU229455 B1 HU 229455B1 HU 0200453 A HU0200453 A HU 0200453A HU P0200453 A HUP0200453 A HU P0200453A HU 229455 B1 HU229455 B1 HU 229455B1
Authority
HU
Hungary
Prior art keywords
castor oil
undecanoate
solution
liquid carrier
formulation
Prior art date
Application number
HU0200453A
Other languages
English (en)
Hungarian (hu)
Inventor
De Henrik Nijs
Susan Chandler
Elizabeth Anne Perry
Josephine Joan Christine Ferdinando
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of HUP0200453A2 publication Critical patent/HUP0200453A2/hu
Publication of HUP0200453A3 publication Critical patent/HUP0200453A3/hu
Publication of HU229455B1 publication Critical patent/HU229455B1/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16Masculine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Fats And Perfumes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0200453A 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil HU229455B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99302581 1999-04-01
PCT/EP2000/002677 WO2000059512A1 (en) 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil

Publications (3)

Publication Number Publication Date
HUP0200453A2 HUP0200453A2 (hu) 2002-07-29
HUP0200453A3 HUP0200453A3 (en) 2003-06-30
HU229455B1 true HU229455B1 (en) 2013-12-30

Family

ID=8241306

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0200453A HU229455B1 (en) 1999-04-01 2000-03-27 Formulation comprising testosteron undecanoate and castor oil

Country Status (26)

Country Link
EP (1) EP1189620B1 (enExample)
JP (1) JP2002541111A (enExample)
KR (1) KR100666016B1 (enExample)
CN (1) CN1155385C (enExample)
AT (1) ATE269708T1 (enExample)
AU (1) AU768537B2 (enExample)
BR (1) BR0009465A (enExample)
CA (1) CA2366856C (enExample)
CZ (1) CZ298573B6 (enExample)
DE (1) DE60011771T2 (enExample)
DK (1) DK1189620T3 (enExample)
ES (1) ES2222199T3 (enExample)
HU (1) HU229455B1 (enExample)
ID (1) ID30481A (enExample)
IL (2) IL145524A0 (enExample)
MX (1) MXPA01009919A (enExample)
NO (1) NO329420B1 (enExample)
NZ (1) NZ514290A (enExample)
PL (1) PL195163B1 (enExample)
PT (1) PT1189620E (enExample)
RU (1) RU2246296C2 (enExample)
SK (1) SK286071B6 (enExample)
TR (1) TR200102769T2 (enExample)
TW (1) TWI280124B (enExample)
WO (1) WO2000059512A1 (enExample)
ZA (1) ZA200107781B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907715D0 (en) * 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
US6652880B1 (en) 1999-04-01 2003-11-25 R.P. Scherer Technologies, Inc. Oral pharmaceutical compositions containing long-chain triglycerides and liphophilic surfactants
JO2505B1 (en) 2003-03-14 2009-10-05 باير شيرنغ فارما اكتنجيسيلشافت Pharmacy methods and formulations for obtaining acceptable serum testosterone levels
US8784869B2 (en) 2003-11-11 2014-07-22 Mattern Pharma Ag Controlled release delivery system for nasal applications and methods of treatment
ES2258694T3 (es) * 2003-11-11 2006-09-01 Mattern, Udo Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales.
US20060140820A1 (en) 2004-12-28 2006-06-29 Udo Mattern Use of a container of an inorganic additive containing plastic material
US8241664B2 (en) * 2005-04-15 2012-08-14 Clarus Therapeutics, Inc Pharmaceutical delivery systems for hydrophobic drugs and compositions comprising same
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
RU2480208C2 (ru) 2006-10-04 2013-04-27 М Унд П Патент Акциенгезелльшафт Система доставки с контролируемым высвобождением для назального применения нейротрансмиттеров
GB0818473D0 (en) 2008-10-08 2008-11-12 Probio Nutraceuticals As Composition
US11304960B2 (en) * 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
PH12012502016A1 (en) * 2010-04-12 2013-01-21 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
GB201006200D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US9119772B2 (en) * 2011-01-26 2015-09-01 Allergan, Inc. Androgen composition for treating an opthalmic condition
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
EP3157505B1 (en) 2014-06-17 2019-07-24 Merck Sharp & Dohme B.V. Stable formulations of testosterone undecanoate
JP6723166B2 (ja) * 2014-06-19 2020-07-15 ソルラル ファーマ エーピーエス 親油性の化合物の固体経口剤形
WO2016033556A1 (en) 2014-08-28 2016-03-03 Lipocine Inc. BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
US20170246187A1 (en) 2014-08-28 2017-08-31 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
RU2017111503A (ru) * 2014-08-29 2018-10-05 Липосин Инк. КОМПОЗИЦИИ(17-β)-3-ОКСОАНДРОСТ-4-ЕН-17-ИЛ УНДЕКАНОАТА И СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ
US20160361322A1 (en) 2015-06-15 2016-12-15 Lipocine Inc. Composition and method for oral delivery of androgen prodrugs
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy
AU2019308326B2 (en) * 2018-07-20 2025-07-31 Lipocine Inc. Liver disease

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
GB9415810D0 (en) * 1994-08-04 1994-09-28 Jerrow Mohammad A Z Composition
GB9608719D0 (en) * 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
SE9700642D0 (sv) * 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet

Also Published As

Publication number Publication date
ID30481A (id) 2001-12-13
CZ298573B6 (cs) 2007-11-14
MXPA01009919A (es) 2002-04-24
IL145524A0 (en) 2002-06-30
JP2002541111A (ja) 2002-12-03
HK1043544A1 (en) 2002-09-20
EP1189620A1 (en) 2002-03-27
SK286071B6 (sk) 2008-02-05
NO329420B1 (no) 2010-10-18
CA2366856A1 (en) 2000-10-12
IL145524A (en) 2006-12-31
NO20014718D0 (no) 2001-09-28
AU4111100A (en) 2000-10-23
KR100666016B1 (ko) 2007-01-10
PL195163B1 (pl) 2007-08-31
HUP0200453A3 (en) 2003-06-30
CA2366856C (en) 2006-05-16
DK1189620T3 (da) 2004-08-16
DE60011771T2 (de) 2004-11-04
TR200102769T2 (tr) 2002-05-21
TWI280124B (en) 2007-05-01
KR20010108435A (ko) 2001-12-07
BR0009465A (pt) 2002-01-08
ATE269708T1 (de) 2004-07-15
CN1155385C (zh) 2004-06-30
CN1346274A (zh) 2002-04-24
CZ20013507A3 (cs) 2002-03-13
DE60011771D1 (de) 2004-07-29
PT1189620E (pt) 2004-10-29
NZ514290A (en) 2003-08-29
NO20014718L (no) 2001-09-28
HUP0200453A2 (hu) 2002-07-29
ZA200107781B (en) 2002-12-20
PL351259A1 (en) 2003-04-07
RU2246296C2 (ru) 2005-02-20
ES2222199T3 (es) 2005-02-01
AU768537B2 (en) 2003-12-18
EP1189620B1 (en) 2004-06-23
WO2000059512A1 (en) 2000-10-12
SK13722001A3 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
HU229455B1 (en) Formulation comprising testosteron undecanoate and castor oil
RU2001129362A (ru) Композиция, включающая ундеканоат тестостерона и касторовое масло
GB9907715D0 (en) Pharmaceutical compositions
EP0904064B1 (en) Oral pharmaceutical compositions containing sex hormones
CA2185347A1 (en) A carrier for hydrophobic drugs and a pharmaceutical composition based thereon
PL318560A1 (en) Novel orally administered preparations containing cyclosporin of simple composition and high bioavailability
HUP0001013A2 (hu) Ciklosporin A-t tartalmazó olajmentes gyógyászati készítmények
CA2388609A1 (en) Oxcarbazepine formulations for administration with or without food
CA2301017A1 (en) Use of propyl gallate to increase bioavailability of orally administered pharmaceutical compounds
CA2431397A1 (en) Self emulsifying lipid matrix (selm)
NO950134L (no) Formuleringer for oralt administrerte farmasöytiske midler
WO2004073592A3 (en) Semi-solid immediate-release oral formulations comprising an anticancer hydrophobic agent, a polyglycolised glyceride and a hydrophilic carrier
AR023235A1 (es) Formulaciones de androgenos
US20060024341A1 (en) Microemulsion composition and related method
TH33003B (th) สูตรตำรับแอนโดรเจน
TH60756A (th) สูตรตำรับแอนโดรเจน
TH34374B (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
TH40043A (th) องค์ประกอบเชิงเภสัชกรรมชนิดที่เป็นของแข็งซึ่งประกอบด้วยอนุพันธ์เบนโซฟูแรน
MY130474A (en) Oral pharmaceutical compositions containing long-chain triglycerides and lipophilic surfactants
HK1043544B (en) Formulation comprising testosteron undecanoate and castor oil
MX9802026A (es) Formulaciones farmaceuticas que contienen darifenacina.

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: N.V. ORGANON, NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL

GB9A Succession in title

Owner name: MSD OSS B.V., NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL; N.V. ORGANON, NL

GB9A Succession in title

Owner name: MERCK SHARP & DOHME B.V., NL

Free format text: FORMER OWNER(S): AKZO NOBEL N.V., NL; MSD OSS B.V., NL; N.V. ORGANON, NL